参考文献
1: Rampias T, Favicchio R, Stebbing J, Giamas G. Targeting tumor-stroma
crosstalk: the example of the NT157 inhibitor. Oncogene. 2016 May
19;35(20):2562-4. doi: 10.1038/onc.2015.392. Epub 2015 Oct 19. PubMed PMID:
26477311.
2: Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K,
Levitzki A, Karin M. Targeting colorectal cancer via its microenvironment by
inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling.
Oncogene. 2016 May 19;35(20):2634-44. doi: 10.1038/onc.2015.326. Epub 2015 Sep
14. PubMed PMID: 26364612; PubMed Central PMCID: PMC4791217.
3: Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y,
Bar-Eli M, Reuveni H, Levitzki A. Targeting melanoma with NT157 by blocking Stat3
and IGF1R signaling. Oncogene. 2016 May 19;35(20):2675-80. doi:
10.1038/onc.2015.229. Epub 2015 Jun 29. PubMed PMID: 26119932.
4: Garofalo C, Capristo M, Mancarella C, Reunevi H, Picci P, Scotlandi K.
Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma
Cell Lines. Front Endocrinol (Lausanne). 2015 May 13;6:74. doi:
10.3389/fendo.2015.00074. eCollection 2015. PubMed PMID: 26029165; PubMed Central
PMCID: PMC4429561.
5: Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME,
Levitzki A, Cox ME. The tyrphostin NT157 suppresses insulin receptor substrates
and augments therapeutic response of prostate cancer. Mol Cancer Ther. 2014
Dec;13(12):2827-39. doi: 10.1158/1535-7163.MCT-13-0842. Epub 2014 Sep 29. PubMed
PMID: 25267499.
